IMBCR & Emory University’s Big Discovery!
Multiple myeloma (MM) patients are at higher risk for severe COVID-19. Their mRNA vaccination response…
read moreMultiple myeloma (MM) patients are at higher risk for severe COVID-19. Their mRNA vaccination response…
read moreJanuary 19, 2021 WEST HOLLYWOOD, CA, January 19, 2021 – ONCOtherapeutics and Dr. James Berenson…
read moreNew name, logo, and business unit alignment introduced as part of an extensive rebranding initiative…
read moreSerum BCMA to Determine Disease Progression in RRMM Patients Sponsor: Incyte Protocol Number: I-RUX-19-52 Start…
read moreA Pilot Study Examining Selinexor’s Ability to Overcome Resistance in Multiple Myeloma Patients Who Are…
read moreA Randomized Phase 2 Study of Peri-Operative Ipilimumab, Nivolumab and Cryoablation Versus Standard Peri-Operative Care…
read moreNeoadjuvant Her2-targeted Therapy and Immunotherapy with Pembrolizumab Sponsor: Merck/Cedars-Sinai Protocol Number: 2018-04-McArthur-neoHP Start Date: 11/15/2019…
read moreA Phase 2 Study of Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to…
read moreA Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination with Pomalidomide,…
read moreA Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients Sponsor: Incyte Protocol…
read more